Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06153251 is registered in ClinicalTrials.gov with Juno Therapeutics, Inc., a Bristol-Myers Squibb Company as lead sponsor.

NCT NCT06153251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06153251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase
Phase 1
Overall status
Recruiting
Start date
January 23, 2024
Completion date
May 2, 2030
Enrollment
187 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed and/or refractory multiple myeloma